Shareholders in Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) may be thrilled to learn that the analysts have just...
DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection
Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) shareholders will have a reason to smile today, with the analysts making...